Implementation Science to Achieve Equity in Heart Failure Care
Published: April 03, 2024
- Guideline-directed medical therapies (GDMT) and non-pharmacologic therapies improve quality of life and survival in patients with HF, but there are disparities in treatment particularly for women and those from underrepresented racial and ethnic groups.
- This statement provides an overview of implementation trials in HF, assesses the use of conceptual frameworks and health equity principles, and provides pragmatic guidance for equity in HF.
- Implementation science provides a pivotal opportunity to close HF gaps in treatment when developed with equity as the focus.
Supporting Materials
- Commentary: A Call to Action Toward Equity in Heart Failure: Implementation Science as Tool for Change by Quentin R. Youmans, MD, MSc; Hector Ventura, MD
- Top Things to Know: Implementation Science to Achieve Equity in HF Care
Recommended Reading
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- Implementation Strategies to Improve Blood Pressure Control in the United States
- Leveraging Implementation Science for Cardiovascular Health Equity
- Implementation of Prevention Science to Eliminate Health Care Inequities in Achieving Cardiovascular Health
- 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure